

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

NCT07264426

Status RECRUITING
Sponsor argenx
Enrollment 200 participants

Key Eligibility Criteria

Inclusion (4)

- Aged ≥18 years at time of providing informed consent
- Diagnosed with CIDP
- Planned to be receiving efgartigimod treatment within the CIDP treatment label of efgartigimod in the participant's respective country
- Efgartigimod treatment-naïve at time of screening

Exclusion (2)

- Polyradiculoneuropathy due to any other cause(s)
- Current participation in any interventional clinical study at time of screening, or planned participation before initiation of efgartigimod

Locations (19 total)

PPD Virtual, Wilmington, North Carolina, United States
Jüdisches Krankenhaus Berlin, Berlin, Germany
Universitätsklinikum Düsseldorf, Düsseldorf, Germany
... and 16 more locations